Vinícius Augusto Campos Péret, Adriana Cotta Cardoso Reis, Lívia da Cunha Agostini, Isadora Oliveira Ansaloni Pereira, Glenda Nicioli da Silva, Diogo Teixeira Carvalho, Stefânia Neiva Lavorato, Saulo Fehelberg Pinto Braga, Geraldo Célio Brandão, Thiago Belarmino de Souza
{"title":"Benzoxazoles Derived from Eugenol as Potential Agents against Arboviruses: Synthesis, Antiviral Studies, and Mechanistic Insights.","authors":"Vinícius Augusto Campos Péret, Adriana Cotta Cardoso Reis, Lívia da Cunha Agostini, Isadora Oliveira Ansaloni Pereira, Glenda Nicioli da Silva, Diogo Teixeira Carvalho, Stefânia Neiva Lavorato, Saulo Fehelberg Pinto Braga, Geraldo Célio Brandão, Thiago Belarmino de Souza","doi":"10.1002/cmdc.202500323","DOIUrl":null,"url":null,"abstract":"<p><p>The synthesis of new eugenol-benzoxazole derivatives and their antiviral evaluation against Orthoflavivirus zikaense (ZIKV), Alphavirus chikungunya (CHIKV), and Alphavirus mayaro (MAYV) are reported. Derivative 16 shows the highest potency and selectivity indices: 25 for ZIKV (EC<sub>50</sub>: 6.1 µM), 11 for CHIKV (EC<sub>50</sub>: 14.2 µM), and 24 for MAYV (EC<sub>50</sub>: 6.3 µM), 68 times more potent than ribavirin and amantadine drugs. RT-qPCR showed that benzoxazole 16 reduced the viral load of CHIKV after 24 and 48 h and of ZIKV after 24 h, demonstrating that it may be a promising antiviral agent. In cytopathic effect assays, benzoxazoles 16 and 23 showed cell monolayer protection against ZIKV and compounds 16 and 24 against CHIKV. None of these compounds showed virucidal activity, suggesting they act post-viral entry, targeting proteins related to viral replication rather than inactivating the virus before cellular infection. Molecular dynamics and MM/GBSA binding energy analysis of compound 16 on viral replication targets identified the capsid protein and nsP3 as the most promising targets, with binding free energies of -31.21 and -29.55 kcal/mol, respectively. The ligand remained deeply buried and well-confined in both binding sites, with minimal positional drift and a marked reduction in solvent-accessible surface area.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500323"},"PeriodicalIF":3.4000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202500323","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The synthesis of new eugenol-benzoxazole derivatives and their antiviral evaluation against Orthoflavivirus zikaense (ZIKV), Alphavirus chikungunya (CHIKV), and Alphavirus mayaro (MAYV) are reported. Derivative 16 shows the highest potency and selectivity indices: 25 for ZIKV (EC50: 6.1 µM), 11 for CHIKV (EC50: 14.2 µM), and 24 for MAYV (EC50: 6.3 µM), 68 times more potent than ribavirin and amantadine drugs. RT-qPCR showed that benzoxazole 16 reduced the viral load of CHIKV after 24 and 48 h and of ZIKV after 24 h, demonstrating that it may be a promising antiviral agent. In cytopathic effect assays, benzoxazoles 16 and 23 showed cell monolayer protection against ZIKV and compounds 16 and 24 against CHIKV. None of these compounds showed virucidal activity, suggesting they act post-viral entry, targeting proteins related to viral replication rather than inactivating the virus before cellular infection. Molecular dynamics and MM/GBSA binding energy analysis of compound 16 on viral replication targets identified the capsid protein and nsP3 as the most promising targets, with binding free energies of -31.21 and -29.55 kcal/mol, respectively. The ligand remained deeply buried and well-confined in both binding sites, with minimal positional drift and a marked reduction in solvent-accessible surface area.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.